Cambodia Leads Asia-Pacific with Revolutionary HIV Prevention Injection
PHNOM PENH – In a landmark achievement for public health,Cambodia has become the first nation in the Asia-Pacific region to offer Cabotegravir,a long-acting injectable medication for pre-exposure prophylaxis (PrEP) against HIV [[1]]. Officially announced by the Ministry of Health on june 27th, this innovative approach promises a significant boost to HIV prevention efforts nationwide.
A Game-Changer for At-Risk Populations
Cabotegravir (CAB-PrEP) requires only a single injection every two months, offering sustained protection against HIV infection. This is particularly crucial for individuals at higher risk, including female sex workers, transgender individuals, men who have sex with men, and those who use intravenous drugs. The medication provides a discreet and convenient alternative to daily oral prep pills, boasting an remarkable 95% effectiveness rate in preventing HIV transmission.
First Mover Advantage & Regional Impact
This rollout positions Cambodia as a regional leader in adopting cutting-edge HIV prevention strategies. The ministry of Health emphasized that CAB-PrEP is now a key component of a broader, multi-faceted HIV prevention programme, offering diverse protection options to those who need them most.”UNAIDS is thrilled and deeply honoured to stand alongside the Ministry of Health…to celebrate the official launch of long-acting injectable cabotegravir (CAB-LA) as a new and innovative option for HIV prevention in Cambodia,” stated UNAIDS Cambodia in a released statement.
Looking Ahead
The launch, presided over by health ministry secretary of state Youk Sambath, was attended by key stakeholders including Patricia Ongpin, UNAIDS country director for Cambodia, Laos and Malaysia. This collaborative effort signals a strong commitment to combating HIV and improving public health outcomes across the region.
Call to Action: Learn more about HIV prevention and resources available in Cambodia at the Ministry of Health website [link to MOH website].